









市場行情
/
股票
/
nasdaq-vtvt
/

vTv Therapeutics Inc

VTVT

37.160USD

+1.150+3.19%

交易中（美東）報價延遲15分鐘

146.34M總市值

虧損本益比TTM



vTv Therapeutics Inc

37.160

+1.150+3.19%

概覽公司財務分析

概覽

公司

財務

分析

關於 vTv Therapeutics Inc 公司

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

vTv Therapeutics Inc簡介



公司代碼VTVT

公司名稱vTv Therapeutics Inc

上市日期Jul 30, 2015

CEOSekhri (Paul Jai)

員工數量23

證券類型Ordinary Share

年結日Jul 30

公司地址3980 Premier Dr

城市HIGH POINT

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編27265

電話13368410300

網址https://vtvtherapeutics.com/

公司代碼VTVT

上市日期Jul 30, 2015

CEOSekhri (Paul Jai)

vTv Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

Mr. Burns Mcclellan

Investor Relations

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

Mr. Daniel (Dan) Spiegelman

Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

收入明細

FY2023

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月5日週五

持股股東

股東類型

持股股東

佔比

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

其他

54.33%

持股股東

佔比

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

其他

54.33%

股東類型

持股股東

佔比

Holding Company

23.18%

Investment Advisor

16.48%

Venture Capital

7.58%

Hedge Fund

4.34%

Investment Advisor/Hedge Fund

0.75%

Individual Investor

0.42%

其他

47.24%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1.15M

29.13%

+562.26K

2025Q2

1.51M

57.66%

-17.51K

2025Q1

1.53M

60.03%

+1.63K

2024Q4

1.51M

61.92%

-7.51K

2024Q3

1.49M

61.31%

+181.69K

2024Q2

1.29M

53.13%

+308.00

2024Q1

1.68M

72.07%

+129.32K

2023Q4

1.40M

68.78%

-52.49K

2023Q3

1.41M

69.35%

-49.61K

2023Q2

1.40M

81.32%

+323.67K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

MacAndrews & Forbes Holdings, Inc.

912.98K

34.88%

Apr 01, 2025

Samsara BioCapital, LLC

312.78K

11.95%

+106.00K

+51.26%

Sep 22, 2025

Trails Edge Capital Partners LP

231.00K

8.83%

+231.00K

Aug 29, 2025

Fidelity Management & Research Company LLC

178.20K

6.81%

Jun 30, 2025

Baker Bros. Advisors LP

148.31K

5.67%

+51.00K

+52.41%

Sep 03, 2025

The Vanguard Group, Inc.

43.17K

1.65%

+1.62K

+3.89%

Jun 30, 2025

Geode Capital Management, L.L.C.

12.87K

0.49%

+229.00

+1.81%

Jun 30, 2025

Northern Trust Investments, Inc.

15.29K

0.58%

-339.00

-2.17%

Jun 30, 2025

Millennium Management LLC

15.04K

0.57%

+15.04K

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

iShares Micro-Cap ETF

佔比0.01%

iShares Core S&P Total U.S. Stock Market ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

公告日期

類型

比率

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

常見問題

vTv Therapeutics Inc的前五大股東是誰？



vTv Therapeutics Inc的前五大股東如下：
MacAndrews & Forbes Holdings, Inc.
持有股份：912.98K
佔總股份比例：34.88%。
Samsara BioCapital, LLC
持有股份：312.78K
佔總股份比例：11.95%。
Trails Edge Capital Partners LP
持有股份：231.00K
佔總股份比例：8.83%。
Fidelity Management & Research Company LLC
持有股份：178.20K
佔總股份比例：6.81%。
Baker Bros. Advisors LP
持有股份：148.31K
佔總股份比例：5.67%。